Mitsui Chemicals to Buy JSR for $8.81 Billion, Target ¥40 Billion

By Grace Kim

Mitsui Chemicals plans to acquire JSR Corporation for approximately $8.81 billion (¥1.3921 trillion), with closing targeted for the second half of fiscal 2027.

Mitsui Chemicals' November 9, 2026 presentation values 100% of JSR's equity at that amount. Mitsui expects to assume approximately $2.84 billion (¥447.9 billion) of interest-bearing debt and other obligations at closing. Based on JSR's fiscal 2026 outlook, the transaction implies an enterprise-value-to-EBITDA multiple of about 16 times. Completion requires regulatory approvals and other applicable requirements.

How will Mitsui Chemicals finance the JSR deal?

Mitsui Chemicals expects to use a $10.38 billion (¥1.64 trillion) bridge loan at closing, then refinance it through debt, equity and other sources. Its financing mix targets approximately 65% debt and 35% equity-related financing and third-party investment.

Mitsui Chemicals' financing plan includes:

• A potential public equity offering of up to $950 million (¥150 billion).
• Approximately $1.90 billion (¥300 billion) in mezzanine financing.
• The Development Bank of Japan will contribute approximately $1.27 billion (¥200 billion) through non-voting preferred shares.

That bank investment forms part of a joint investment with Mitsui Chemicals. The company says divestitures and other initiatives will support debt reduction and financial flexibility after closing. For Mitsui, the permanent funding mix is the immediate execution test.

What does JSR add to Mitsui's chip-materials portfolio?

JSR supplies photoresists, chemical mechanical planarization (CMP) slurries, multilayer materials and deposition precursors for semiconductor manufacturing. Mitsui Chemicals' presentation ranks JSR second globally in semiconductor photoresists. JSR also supplies chemically amplified resist and metal oxide resist technologies for extreme ultraviolet lithography, supporting precise patterning and processing as chip designs become more complex.

Mitsui already offers pellicles, ICROS Tape, specialty chemicals and optical materials. Together, the businesses can serve front-end manufacturing, back-end processing, advanced packaging and optical applications.

Mitsui expects customer relationships, technical expertise and global manufacturing capabilities to accelerate development and cross-selling. It brings polymer science, precision synthesis and materials-manufacturing technology; JSR brings process knowledge, photoresist technology, surface engineering and longstanding relationships with major semiconductor manufacturers. Mitsui expects the combination to broaden its line card for advanced chips and optical products.

How profitable is JSR today?

JSR's Digital Solutions business generated approximately $1.60 billion (¥252.1 billion) in fiscal 2025 sales and $400 million (¥63.2 billion) in operating income before special items, a 25.1% margin.

Its semiconductor-related electronic materials business generated approximately $1.24 billion (¥196 billion) in fiscal 2025 sales.

JSR's broader operations generated approximately $2.79 billion (¥440.7 billion) in fiscal 2025 revenue, versus $2.46 billion (¥388.8 billion) in fiscal 2024. Operating income before special items reached approximately $394 million (¥62.3 billion), compared with an operating loss of $10.1 million (¥1.6 billion) in fiscal 2024. JSR brings scale, a 25.1% digital-solutions margin and a sharp operating-income recovery.

What earnings targets accompany the acquisition?

Mitsui expects the combined information and communications technology (ICT) business to meet three targets:

• At least $823 million (¥130 billion) in operating income before special items by fiscal 2028.
• More than $1.20 billion (¥190 billion) by fiscal 2030.
• Approximately $253 million (¥40 billion) in annual profit improvements by fiscal 2035.

Of the annual improvement, approximately $127 million (¥20 billion) will come from sales growth, including "expanded market share in semiconductor materials and optical products." Another $127 million (¥20 billion) will come from cost optimization across headquarters functions, research and development, and global operating facilities.

Near-term efficiencies will come from organizational integration and cross-selling. Longer-term initiatives will develop materials for advanced semiconductor packaging, expand optical applications and commercialize new products.

Mitsui expects its acquisition strategy to benefit from sustained global semiconductor demand. Industry forecasts cited by the company indicate the market could compound at more than 10% annually, supported by artificial intelligence, data-center infrastructure, advanced computing and other technologies. Mitsui also expects AI-driven demand for specialized materials to extend into industrial automation, robotics and transportation. Mitsui's payoff depends on both market growth and internal execution.

How will Mitsui restructure the wider portfolio?

The acquisition is intended to reduce Mitsui Chemicals' dependence on traditional petrochemicals and increase exposure to higher-growth specialty materials. The company's presentation calls for a "global specialty chemicals business centered on ICT and life and healthcare," with semiconductor materials and life and healthcare products as primary growth businesses.

Mitsui also plans a more independent polymer science business combining basic and green materials with mobility-related operations. It expects the changes to improve profitability and capital efficiency while letting each business group finance its own growth.

Mitsui will evaluate divestitures and restructuring for operations that miss strategic or financial objectives. After closing, it plans to divest JSR's Life Sciences business.

The asset-light program targets businesses with an aggregate enterprise value of at least $2.22 billion (¥350 billion) over the three years after closing. Mitsui says the moves will support debt reduction and improve financial flexibility. For Mitsui, the portfolio reset matters as much to the financing plan as the purchase itself.

What happens to debt and shareholder returns?

Mitsui Chemicals' post-closing balance-sheet targets are explicit:

• Net debt below four times EBITDA and net debt below 1.5 times equity within three years after closing.
• Net debt below three times EBITDA and net debt below one times equity within five years.
• A total shareholder return ratio of at least 40%, supported by dividends and share repurchases.
• A minimum dividend of approximately $0.47 (¥75) per share under the revised capital-allocation framework.

Following integration, Mitsui expects annual operating cash flow to exceed $1.90 billion (¥300 billion), supporting organic growth investment, debt repayment and shareholder returns.

For fiscal 2030, the broader transformation targets group-wide operating income before special items of at least $1.90 billion (¥300 billion), above the previous $1.58 billion (¥250 billion) target. Mitsui also targets earnings per share above approximately $1.90 (¥300) and return on equity above 10%.

If the integration, divestitures and semiconductor-demand assumptions hold, Mitsui says the transaction can build a larger Japan-based specialty-materials competitor while bringing net debt below three times EBITDA within five years.